
Wei Qiu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1482024/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatology Communications, 2022, 6, 1786-1802.	4.3	18
2	Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Reports, 2021, 34, 108765.	6.4	25
3	EPHA2, a promising therapeutic target for hepatocellular carcinoma. Molecular and Cellular Oncology, 2021, 8, 1910009.	0.7	3
4	Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma. Liver Research, 2021, 5, 195-203.	1.4	3
5	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. Journal of Hepatology, 2021, 75, 888-899.	3.7	45
6	Endothelin-1–Mediated Drug Resistance in <i>EGFR</i> -Mutant Non-Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4224-4232.	0.9	12
7	ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Gastroenterology, 2020, 159, 289-305.e16.	1.3	22
8	Focal Adhesion Kinase Promotes Hepatic Stellate Cell Activation by Regulating Plasma Membrane Localization of TGFβ Receptor 2. Hepatology Communications, 2020, 4, 268-283.	4.3	8
9	REPLY:. Hepatology, 2019, 70, 1495-1496.	7.3	0
10	Focal Adhesion Kinase and β atenin Cooperate to Induce Hepatocellular Carcinoma. Hepatology, 2019, 70, 1631-1645.	7.3	38
11	Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation. Cell Death and Disease, 2018, 9, 558.	6.3	28
12	Inhibition of insulinâ€like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatology Communications, 2018, 2, 732-746.	4.3	21
13	ABL1 is Overexpressed and Activated in Hepatocellular Carcinoma. Journal of Cancer and Tumor International, 2017, 6, 1-8.	0.1	5
14	FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma. Gene Expression, 2016, 17, 79-88.	1.2	16
15	FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy. Scientific Reports, 2016, 6, 34316.	3.3	10
16	Inhibition of SIRT2 suppresses hepatic fibrosis. American Journal of Physiology - Renal Physiology, 2016, 310, G1155-G1168.	3.4	35
17	FAK Is required for câ€Met/βâ€cateninâ€driven hepatocarcinogenesis. Hepatology, 2015, 61, 214-226.	7.3	66
18	BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16520-16525.	7.1	24

Wei Qiu

#	Article	IF	CITATIONS
19	PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology, 2011, 54, 1249-1258.	7.3	78
20	Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20027-20032.	7.1	93
21	PUMA Regulates Intestinal Progenitor Cell Radiosensitivity and Gastrointestinal Syndrome. Cell Stem Cell, 2008, 2, 576-583.	11.1	199